|Targets||Melanocortin (MC) Receptors|
|Description||JNJ10229570 is a novel MC1R and MC5R antagonist. It was used to treat primary human sebaceous cells. It might have a potential for the treatment of acne and other sebaceous gland pathologies. It was developed by Johnson & Johnson. It was in phase II clinical trials, but has been terminated.|
|Solubility||Soluble in DMSO, not in water|
|Application||JNJ10229570 was used to treat primary human sebaceous cells. It might have a potential for the treatment of acne and other sebaceous gland pathologies.|
|Quality Standard||In-house standard|
|Boiling Point||541.2±60.0 °C | Condition: Press: 760 Torr|
|Density||1.22±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||JNJ10229570 was developed by Johnson & Johnson. It was in phase II clinical trials, but has been terminated.|
JNJ10229570 is a novel MC1R and MC5R antagonist. It was used to treat primary human sebaceous cells. It might have a potential for the treatment of acne and oth...
SHU 9119 is a potent antagonist at human melanocortin 3 (IC50= 0.23 nM) and 4 receptors (IC50= 0.06 nM), and a partial agonist at the hMC5R (IC50= 0.09 nM)
Bremelanotide Acetate is a heptapeptide melanocortin agonist. Bremelanotide, formerly known as PT-141, employed in clinical trials for sexual dysfunction includ...